DiaMedica Therapeutics Inc.

We're thrilled to announce that DiaMedica Therapeutics has received regulatory approval to initiate our Phase 2 trial of DM199 in the treatment of preeclampsia. This is a critical step forward for a condition that impacts millions of pregnancies worldwide. First patient dosing is expected in Q4 2024, with proof-of-concept results targeted for the first half of 2025. Read the full press release here: https://bit.ly/47XFGqw Follow us on this important journey to improve maternal and fetal health outcomes! 🌟 #Preeclampsia #WomensHealth #ClinicalTrials #DiaMedica $DMAC

We're #hiring a new Accounts Payable Specialist in Minnetonka, Minnesota. Apply today or share this post with your network.

📢 DiaMedica Therapeutics (Nasdaq: DMAC) is excited to announce our participation in two key investor conferences this September. Join us at the HC Wainwright Global Investment Conference (Sept 9-11) where we’ll present on Sept 9 at 3:00 PM ET and hold one-on-one meetings. We’ll also be at the Lake Street Best Ideas Growth (Big8) Conference (Sept 12) for more one-on-one meetings. Read more on our latest press release here: https://bit.ly/3ZvgPZh #Biotech #Diamedica #Investment #Stroke #Preeclampsia $DMAC

We have just released our latest business update and second quarter 2024 financial results. 🔗Read our latest press release here: https://bit.ly/3M3kLrT Join us for a conference call and webcast to discuss these updates in detail: 📅 Date: Thursday, August 8, 2024 🕖 Time: 7:00 AM CT / 8:00 AM ET 🌐 Web access: https://lnkd.in/guB9vibK 📞 Dial In: (646) 357-8785 🆔 Conference ID: 35082 Key Highlights: - AIS Phase 2/3 ReMEDy2 Trial: Interim Enrollment (n=144) targeted for Q1 2025 - Preeclampsia Phase 2 Trial: Starting Q4 2024 with proof-of-concept results targeted for H1 2025 - Completed $12 Million Private Placement: Extending cash runway into Q3 2026 Stay tuned for more updates and join us for the call! #DiaMedica #BusinessUpdate #FinancialResults #ConferenceCall $DMAC

We are pleased to announce that we will be providing a business update and reporting our second quarter 2024 financial results on August 8, 2024. Read our most recent press release here: https://bit.ly/3SuZkne Join our conference call for all the details: 📅 Date: Thursday, August 8, 2024 🕖 Time: 7:00 AM CT / 8:00 AM ET 🌐 Web access: https://lnkd.in/guB9vibK 📞 Dial In: (646) 357-8785 🆔 Conference ID: 35082 Stay tuned for insightful updates! #DiaMedica #FinancialResults #BusinessUpdate #ConferenceCall $DMAC

📅 Reminder! Register for our KOL event TODAY! https://lnkd.in/gYa_KxNX #KOL #Preeclampsia #DiaMedica #DM199 #VirtualEvent #LifeSciences #Biotech $DMAC

🚀 Join Us for an Exclusive Virtual KOL Event! We are thrilled to release our comprehensive white paper on preeclampsia and announce an upcoming Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the treatment of preeclampsia. 📅 Event Date: July 29, 2024 10am ET / 9am CT 🎤 Featured Speakers: Prof. Catherine Cluver, MD, PhD (Stellenbosch University) Prof. Stephen Tong, MD, PhD (The University of Melbourne) Prof. Susan Walker, MD, PhD (The University of Melbourne) Our distinguished speakers will delve into the unmet need and current treatment landscape for preeclampsia, offering their valuable insights and expertise. Don't miss this opportunity to learn more about our innovative program and the future of preeclampsia treatment. 👉 Register Now: https://bit.ly/4cyaEXV 📄 White Paper: https://bit.ly/45YPjV8 🔗 Find the full details here in our Press Release: https://bit.ly/3S0JGje #Preeclampsia #DiaMedica #DM199 #RinvecalinaseAlfa #VirtualEvent #KOL #Healthcare #LifeSciences #Biotech $DMAC 

DiaMedica Therapeutics is thrilled to announce the successful closing of an $11.8 million private placement. To read our latest press release, please click here: https://bit.ly/3xwnWFc #DiaMedica #BusinessUpdate #PrivatePlacement $DMAC

DiaMedica Therapeutics announces a successful $11.8 million private placement. Find all the details here on our latest press release: https://bit.ly/4ci9Yph Visit us on our website at www.DiaMedica.com and stay tuned for more updates! 🌟💼 #DiaMedica #BusinessUpdate #PrivatePlacement #AcuteIschemicStroke #ReMEDy2 #Preeclampsia $DMAC

📢 Exciting News! DiaMedica Therapeutics expands DM199 (Rinvecalinase Alfa) program into preeclampsia! Read the full press release here for more details: https://bit.ly/3VNtenU Management will host a conference call on Thursday, June 27, 2024, at 8:00 AM ET / 7:00 AM CT to discuss its clinical expansion into preeclampsia. 📅 Date: Thursday, June 27, 2024 at 8:00 AM ET / 7:00 AM CT 🔗 https://lnkd.in/gxdfQnSV 📞 Conference Call Dial-In: (646) 357-8785 🆔 Conference ID: 53747 Don't miss it! 🌟📰 #Preeclampsia #DiaMedica #DM199 $DMAC